Patient selection
prostate cancer
PROSTATE CANCER
This retrospective study was approved by our institutional review board and the requirement for written informed consent was waived. We reviewed the medical records of our institutional database to identify patients who had the suspicion of PCa (with PSA levels > 4 ng/mL). Those who underwent mpMRI and subsequent MRGB between February 2017 and October 2021 were considered potentially eligible. Initially, 401 consecutive patients were identified, of them 77 were excluded for reasons as follows: (1) with PCa diagnosis or treatment prior to MRI (
Flowchart of the study population with the exclusion criteria. csPCa, clinically significant prostate cancer